Guoyuan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guoyuan Li has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Haowei Lu
Ward 2, Department of Medical Oncology, Lixin People’s Hospital, Bozhou City, Anhui Province, China
1 shared publication Heren Wang
Graduate School of Qinghai University, Xining, Qinghai, China
1 shared publication- Jun Jiang
Department of Medical Oncology, Qinghai University Affiliated Hospital, Xining, China
1 shared publication - Weixing Zhao
Department of Oncology, Graduate School of Qinghai University, Qinghai, China
1 shared publication - Xiaoni Jin
Graduate School of Qinghai University
1 shared publication - Xingfa Huo
Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, China
1 shared publication
Latest Publications
- Open Access
- 14 April 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives
Background: Limited-stage small cell lung cancer (LS-SCLC) is a highly aggressive tumor characterized by a poor prognosis. While concurrent chemoradiotherapy (CCRT) remains the standard treatment, the high rates of recurrence and poor long-term survival highlight the pressing need for novel therapeutic approaches. Purpose: In recent years, the introduction of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has opened new avenues for the treatment of LS-SCLC. This review highlights the clinical advancements of ICIs in CCRT, consolidation therapy, and neoadjuvant therapy, emphasizing their potential to improve progression-free survival (PFS) and overall survival (OS). This review also discusses management of immunotherapy-related side effects. Research Design: This is a review article that synthesizes recent research findings on immunotherapy for LS-SCLC. Study Sample: Not applicable (review of existing literature). Data Collection and/or Analysis: This review summarizes key studies exploring the application of immunotherapy in limited-stage small cell lung cancer.Additionally, it examines the role of the tumor microenvironment, tumor mutation burden (TMB), and Programmed cell death 1 ligand 1(PD-L1) as biomarkers for predicting the efficacy of immunotherapy. Results: This review emphasizes their potential to improve PFS and OS. Conclusions: Despite the significant advancements in research, the use of ICIs in LS-SCLC continues to face challenges, including the identification of optimal treatment regimens, validation of long-term efficacy, and development of personalized predictive biomarkers. Future research should prioritize large-scale, multicenter clinical trials to refine combination therapy strategies, establish customized treatment approaches, and enhance patient outcomes.
- 14 April 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Open AccessImmunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives
Background: Limited-stage small cell lung cancer (LS-SCLC) is a highly aggressive tumor characterized by a poor prognosis. While concurrent chemoradiotherapy (CCRT) remains the standard treatment, the high rates of recurrence and poor long-term survival highlight the pressing need for novel therapeutic approaches. Purpose: In recent years, the introduction of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has opened new avenues for the treatment of LS-SCLC. This review highlights the clinical advancements of ICIs in CCRT, consolidation therapy, and neoadjuvant therapy, emphasizing their potential to improve progression-free survival (PFS) and overall survival (OS). This review also discusses management of immunotherapy-related side effects. Research Design: This is a review article that synthesizes recent research findings on immunotherapy for LS-SCLC. Study Sample: Not applicable (review of existing literature). Data Collection and/or Analysis: This review summarizes key studies exploring the application of immunotherapy in limited-stage small cell lung cancer.Additionally, it examines the role of the tumor microenvironment, tumor mutation burden (TMB), and Programmed cell death 1 ligand 1(PD-L1) as biomarkers for predicting the efficacy of immunotherapy. Results: This review emphasizes their potential to improve PFS and OS. Conclusions: Despite the significant advancements in research, the use of ICIs in LS-SCLC continues to face challenges, including the identification of optimal treatment regimens, validation of long-term efficacy, and development of personalized predictive biomarkers. Future research should prioritize large-scale, multicenter clinical trials to refine combination therapy strategies, establish customized treatment approaches, and enhance patient outcomes.
- Open Access
- 7 September 2022
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 50 (9)
Case report of double superior vena cava and double odd vein with hypoplastic left brachiocephalic vein
Persistent left superior vena cava (PLSVC) is a common venous variation that is usually accompanied by an absence of the left brachiocephalic vein, and displays a higher incidence in patients with congenital heart disease. Here, the case of a 57-year-old male patient who was found to have PLSVC on chest computed tomography (CT) during screening for gastric cancer metastasis at the Affiliated Hospital of Qinghai University, is described. Further coronal CT and three-dimensional reconstruction of the chest revealed the patient's double superior vena cava (DSVC), double odd veins, and left brachiocephalic vein dysplasia. The patient did not have congenital heart disease and the case was associated with dysplasia of the left brachiocephalic vein, indicating an unusual and rare venous abnormality. At the time of writing, the patient was receiving antitumour therapy.
- 7 September 2022
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 50 (9)
Open AccessCase report of double superior vena cava and double odd vein with hypoplastic left brachiocephalic vein
Persistent left superior vena cava (PLSVC) is a common venous variation that is usually accompanied by an absence of the left brachiocephalic vein, and displays a higher incidence in patients with congenital heart disease. Here, the case of a 57-year-old male patient who was found to have PLSVC on chest computed tomography (CT) during screening for gastric cancer metastasis at the Affiliated Hospital of Qinghai University, is described. Further coronal CT and three-dimensional reconstruction of the chest revealed the patient's double superior vena cava (DSVC), double odd veins, and left brachiocephalic vein dysplasia. The patient did not have congenital heart disease and the case was associated with dysplasia of the left brachiocephalic vein, indicating an unusual and rare venous abnormality. At the time of writing, the patient was receiving antitumour therapy.